These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34432315)

  • 41. Far-infrared Radiation Improves Motor Dysfunction and Neuropathology in Spinocerebellar Ataxia Type 3 Mice.
    Liu SW; Chang JC; Chuang SF; Liu KH; Cheng WL; Chang HJ; Chang HS; Lin TT; Hsieh CL; Lin WY; Hsieh M; Kuo SJ; Liu CS
    Cerebellum; 2019 Feb; 18(1):22-32. PubMed ID: 29725949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Machado Joseph disease severity is linked with gut microbiota alterations in transgenic mice.
    Gamage HKAH; Robinson KJ; Luu L; Paulsen IT; Laird AS
    Neurobiol Dis; 2023 Apr; 179():106051. PubMed ID: 36822548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease.
    Costa Mdo C; Luna-Cancalon K; Fischer S; Ashraf NS; Ouyang M; Dharia RM; Martin-Fishman L; Yang Y; Shakkottai VG; Davidson BL; Rodríguez-Lebrón E; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1898-908. PubMed ID: 23765441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
    Abeditashi M; Weber JJ; Pereira Sena P; Velic A; Kalimeri M; Incebacak Eltemur RD; Schmidt J; Hübener-Schmid J; Hauser S; Macek B; Riess O; Schmidt T
    Cell Mol Life Sci; 2022 Jul; 79(8):401. PubMed ID: 35794401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
    Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
    Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue-Specific Vulnerability to Apoptosis in Machado-Joseph Disease.
    Ferreira AF; Raposo M; Shaw ED; Ashraf NS; Medeiros F; Brilhante MF; Perkins M; Vasconcelos J; Kay T; Costa MDC; Lima M
    Cells; 2023 May; 12(10):. PubMed ID: 37408238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebellar morphometric and spectroscopic biomarkers for Machado-Joseph Disease.
    Miranda CO; Nobre RJ; Paiva VH; Duarte JV; Castelhano J; Petrella LI; Sereno J; Santana M; Afonso S; Januário C; Castelo-Branco M; de Almeida LP
    Acta Neuropathol Commun; 2022 Mar; 10(1):37. PubMed ID: 35305685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia.
    Gonçalves N; Simões AT; Prediger RD; Hirai H; Cunha RA; Pereira de Almeida L
    Ann Neurol; 2017 Mar; 81(3):407-418. PubMed ID: 28032667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado-Joseph disease models.
    Marcelo A; Brito F; Carmo-Silva S; Matos CA; Alves-Cruzeiro J; Vasconcelos-Ferreira A; Koppenol R; Mendonça L; de Almeida LP; Nóbrega C
    Hum Mol Genet; 2019 Jan; 28(1):51-63. PubMed ID: 30219871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.
    Koch P; Breuer P; Peitz M; Jungverdorben J; Kesavan J; Poppe D; Doerr J; Ladewig J; Mertens J; Tüting T; Hoffmann P; Klockgether T; Evert BO; Wüllner U; Brüstle O
    Nature; 2011 Nov; 480(7378):543-6. PubMed ID: 22113611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of FKH-2/FOXG1 is neuroprotective in a C. elegans model of Machado-Joseph disease.
    Fardghassemi Y; Parker JA
    Exp Neurol; 2021 Mar; 337():113544. PubMed ID: 33290777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent therapeutic prospects for Machado-Joseph disease.
    Costa MDC
    Curr Opin Neurol; 2020 Aug; 33(4):519-526. PubMed ID: 32657894
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Lee JH; Lin SY; Liu JW; Lin SZ; Harn HJ; Chiou TW
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.
    Chen YS; Hong ZX; Lin SZ; Harn HJ
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
    Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
    Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
    Rajamani K; Liu JW; Wu CH; Chiang IT; You DH; Lin SY; Hsieh DK; Lin SZ; Harn HJ; Chiou TW
    Neuropharmacology; 2017 May; 117():434-446. PubMed ID: 28223212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.